PeptiCov

PeptiCov Overview

PeptiCov is focused on discovering and developing an effective treatment for SARS-CoV-2. PeptiCov is a spin-off company of PeptiCom, a biotechnology company that uses artificial intelligence to streamline peptide drug discovery. PeptiCom's AI technology streamlines and significantly accelerates the ability to discover advanced peptide-based drug candidates by searching an enormous set of possible solutions, vastly reducing the risk of failure during development. It covers more possible molecular options, while simultaneously filtering out the most suitable candidates with properties such as solubility and permeability. This software analyzed several protein targets related to the coronavirus SARS-CoV-2 and designed a number of potential peptide drug candidates that were lab validated. PeptiCov is responsible for further development of these peptides and seeking partnerships with pharmaceutical companies.

Latest News

Mar 10, 2021 · www.calcalistech.com

growth-positive

Pepticom raises $2.6 million for PeptiCov, spin-off company combatting Covid-19

Pepticom, an AI peptide drug design company, has raised $2.6 million in funding to establish a company called PeptiCov. PeptiCov will use AI technology to design and develop novel peptide molecules to treat the SARS-Cov-2 virus responsible for Covid-19. The funding round was led by the Chartered Group. Pepticoms AI technology streamlines the process of discovering candidates for peptide-based drugs by filtering out the most suitable candidates based on properties such as solubility and permeability. The Chartered Groups Technology division has previously invested in Pepticom and believes in its application of AI for SARS-Cov-2 drug discovery. Pepticom was founded in 2011 and has raised a total of $7.6 million in funding.

Investment

Mar 9, 2021 · www.prnewswire.com

growth-positive

Pepticom's New Spinout Company, PeptiCov, to Focus on COVID-19

Pepticom has raised $2.6 million to establish a company called PeptiCov, which will focus on developing treatments for the SARS-Cov-2 virus. PeptiCov will use Pepticoms AI technology to design and discover novel peptide molecules for the treatment of COVID-19. The funding round was led by the Chartered Group. Pepticoms AI technology streamlines the discovery of advanced peptide-based drug candidates and has already designed potential peptide drug candidates for the SARS-Cov-2 virus. PeptiCov will be responsible for further development of these peptides and will seek partnerships with pharma companies. The Chartered Group has previously invested in Pepticom and other Israeli deep tech companies.

InvestmentPartners

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Professor Racah St, Jerusalem, Israel

Photos & Videos

No files yet

PeptiCov Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info